Mode
Text Size
Log in / Sign up
N/A Completed N=36 Randomized Treatment

Evaluation of a HiRes™ Optima Sound Processing Strategy for the HiResolution™ Bionic Ear

Severe to Profound Hearing Loss · in Adult Users of Advanced Bionics HiResolution™ Bionic Ear System
Source: ClinicalTrials.gov NCT01616576 ↗
Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcomePrimary: Speech Perception With Control and Experimental Conditions Both Tested in Quiet, in Speech-spectrum Noise, and in Multi-talker Babble Noise. — 0.2; 88.3; 88.5; 2.8 Percent Correct

Summary

The purpose of this study is to compare a new sound processing strategy to the current sound processing strategy.

Outcome Measures

OutcomeResultp-value
PRIMARY
Speech Perception With Control and Experimental Conditions Both Tested in Quiet, in Speech-spectrum Noise, and in Multi-talker Babble Noise.
0.2; 88.3; 88.5; 2.8; 61.2; 64.0 —
PRIMARY
Device-related Adverse Events
0; 0 —

Eligibility Criteria

Inclusion Criteria

  • Unilateral or bilateral user of CII/HiRes90K™ implant(s) (minimum of one year in each implanted ear), Harmony™ BTE processor(s) with HiRes Fidelity 120™ (with or without ClearVoice™) as preferred sound processing strategy
  • 18 years of age or older at time of implant
  • Postlingual onset of severe-to-profound hearing loss (≥ 6 years of age)
  • At least moderate open-set speech recognition abilities (defined as CNC word score ≥ 50% in medical records or assessed at the Baseline Visit with implant alone for unilateral users, with both implants together for bilateral users)
  • English language proficiency
  • Willingness to use a Harmony™ BTE processor and refrain from ClearVoice™ use for the duration of the study
  • Willingness and ability to participate in all scheduled procedures outlined in the protocol

Exclusion Criteria

  • Presence of any additional disabilities that would prevent or interfere with participation in the required speech perception testing
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01616576). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search